Article

Delivery in female kidney transplant recipients with hepatitis C virus infection: is it safe for mother and newborn?

Mugla University School of Medicine, Mugla, Turkey.
Progress in transplantation (Aliso Viejo, Calif.) (Impact Factor: 0.69). 06/2012; 22(2):141-4, 154. DOI: 10.7182/pit2012667
Source: PubMed

ABSTRACT The aim of this report is to evaluate whether pregnancy is a risk factor for poor outcome of infection with hepatitis C virus or for allograft deterioration among kidney transplant recipients. The first case was in a 41-year-old pregnant kidney transplant recipient with hypercreatinemia and a history of toxic hepatitis. The second case was treated with interferon before transplant. Tacrolimus-based immunosuppressive regimens were used during the pregnancies. Hypertension complicated both pregnancies, and the pregnancies ended with cesarean delivery at preterm and term with healthy but low-weight newborns. The first patient became positive for hepatitis C virus RNA after pregnancy without a flare in transaminase level. Antibodies to hepatitis C virus were negative in the newborns. In conclusion, pregnancy should be promoted for kidney recipients infected with hepatitis C virus who have stable graft and liver function.

0 Followers
 · 
69 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Women can undergo organ transplantation before or during childbearing years. Most pregnancies have been reported in women with renal allografts, but pregnancy is possible in women with various solid organ transplants. No specific structural malformations have been reported after immunosuppressant use in pregnancy; however, the perinatal risks of hypertension, growth restriction, and preterm delivery exist. Immunosuppressive therapy must be maintained and monitored during pregnancy to prevent rejection. Immunosuppressant therapy for allograft protection continues to change faster than safety information regarding human pregnancy is accumulated. This review discusses the pregnancy management for women with various organ transplants. Each group of recipients must deal with specific issues related to the organ transplanted and the underlying medical condition for which the transplant was necessary. Pregnancy in women with organ transplants is now not only common, but often successful for both mother and infant.
    Obstetrical and Gynecological Survey 04/2004; 59(3):214-22. DOI:10.1097/01.OGX.0000115774.42302.D4 · 2.36 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The prevalence and natural course of chronic hepatitis C virus (HCV) infection was evaluated in 15,250 consecutive pregnant women. The rate of HCV vertical and perinatal transmission was also assessed. The presence of anti-HCV was tested by means of EIA III and confirmed by recombinant immunoblot assay III. Alanine transaminase (ALT), anti–human immunodeficiency virus (HIV), and HCV-RNA were tested during the first month and third trimester of pregnancy, and 6 months after delivery; the same tests were made in all of the newborns of anti-HCV–positive mothers at birth (on cord blood samples) and then at 4-month intervals. Anti-HCV positivity was found in 370 cases (2.4%), 72% of whom were also HCV-RNA–positive. The proportion of women with hypertransaminases decreased from 56.4% at the first examination during the first month of pregnancy to 7.4% in the last trimester, and then increased again after delivery (54.5%), without any concomitant changes in the proportion of those with viremia. The proportion of anti-HCV– and HCV-RNA–positive newborns was 5.1% after 1 year (8 of 155), all of whom had the same genotype as their mother. The rate of HCV transmission was not affected by the type of delivery or feeding, or the HIV status of the mother. The results of this large-scale study confirm previous data in smaller series concerning the prevalence of HCV infection in pregnant women, and strongly support the hypothesis of a favorable (possibly immunomediated) effect of pregnancy on liver cell necrosis in anti-HCV–positive women.
    Hepatology 03/2000; 31(3):751 - 755. DOI:10.1002/hep.510310328 · 11.19 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Hepatitis C virus (HCV) remains a problem within hemodialysis units. This study measures HCV prevalence and seroconversion rates across seven countries and investigates associations with facility-level practice patterns. The study sample was from the Dialysis Outcomes and Practice Patterns Study (DOPPS), a prospective, observational study of adult hemodialysis patients randomly selected from 308 representative dialysis facilities in France, Germany, Italy, Japan, Spain, the United Kingdom, and the United States. Logistic regression was used to model odds of HCV prevalence, and Cox regression was used to model time from study entry to HCV seroconversion. Mean HCV facility prevalence was 13.5% and varied among countries from 2.6% to 22.9%. Increased HCV prevalence was associated with longer time on dialysis, male gender, black race, diabetes, hepatitis B (HBV) infection, prior renal transplant, and alcohol or substance abuse in the previous 12 months. Approximately half of the facilities (55.6%) had no seroconversions during the study period. HCV seroconversion was associated with longer time on dialysis, human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS), HBV infection, and recurrent cellulitis or gangrene. An increase in highly trained staff was associated with lower HCV prevalence (OR = 0.93 per 10% increase, P= 0.003) and risk of seroconversion (RR = 0.92, P= 0.07). Seroconversion was associated with an increase in facility HCV prevalence (RR = 1.36, P < 0.0001), but not with isolation of HCV-infected patients (RR = 1.01, P= 0.99). There are differences in HCV prevalence and rate of seroconversion at the country and the hemodialysis facility level. The observed variation suggests opportunities for improved HCV outcomes.
    Kidney International 07/2004; 65(6):2335-42. DOI:10.1111/j.1523-1755.2004.00649.x · 8.52 Impact Factor